Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribavirin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | EIF4E | P06730 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | TOP1 | P11387 | 1/20 | 1.00 |
| ▸ | PNP | P00491 | 4/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribavirin SCHEMBL1981630 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL326516 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL427229 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL14379766 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL41472 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL12758160 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL18537396 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL3954927 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL21311208 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 | |
| Ribavirin SCHEMBL20806078 | 1.00 | LMNA (1.00) | LMNASMN1; SMN2ALDH1A1TSHRADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | EMORY UNIVERSITY | 2024-07-18 | — | — | US | disclosed |
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | NORTHWESTERN UNIVERSITY (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230241037-A1 | CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT | 1GLOBE HEALTH INST NANJING (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | NORTHWESTERN UNIVERSITY | 2021-05-20 | — | — | US | disclosed |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | NEW LIFE CROP SCIENCES LLC | 2021-05-20 | — | — | US | disclosed |
| US-20190270730-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | UNIV KANSAS (US) | 2019-09-05 | — | — | US | disclosed |
| US-10342817-B2 | Combination therapy using ribavirin as elF4E inhibitor | UNIVERSITE DE MONTREAL (CA) | 2019-07-09 | — | — | US | disclosed |
| US-9828409-B2 | Bridged-cyclo-ProTides as prodrugs of therapeutic nucleosides and nucleotides | ZHONG MINGHONG (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170166557-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | UNIV KANSAS (US) | 2017-06-15 | — | — | US | disclosed |
| US-7615535-B2 | Modulating nitric oxide acitivity with glutathione-dependent formaldehyde dehydrogenase (GS-FDH); for treatment of asthma and impotency, angina, hypertension, and cancer; enzyme inhibitors | DUKE UNIVERSITY (US) | 2009-11-10 | — | — | US | disclosed |
| US-7608597-B2 | Methods and compositions for treating hepatitis C virus | IDENIX PHARMACEUTICALS, INC. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009105258-A1 | OLIGOMER CONJUGATES OF HETEROPENTACYCLIC NUCLEOSIDES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009085267-A1 | ANTIVIRAL COMPOUNDS | EPIPHANY BIOSCIENCES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009086192-A1 | BIODEGRADABLE PHOSPHATE PROTECTED NUCLEOTIDE DERIVATIVES AND THEIR USE AS CANCER, ANTI VIRAL AND ANTI PARASITIC AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| WO-2008052722-A2 | USE OF RIBAVIRIN-CONJUGATES AS AN ANTI-VIRAL DRUG | HEIDELBERG PHARMA AG (DE) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176732-A1 | PROTECTED NUCLEOTIDE ANALOGS | NTPCR, NT5C2, PNP | LMNA 777/4885SMN1; SMN2 581/4885ALDH1A1 941/4885 |
| US-11786542-B2 | Methods for enhancing cytotoxic cancer therapy through modulation of purine biosynthesis pathways | IMPDH1, IMPDH2, AMPD3 | LMNA 3194/4885SMN1; SMN2 2108/4885ALDH1A1 97/4885 |
| US-20090197823-A1 | ALISKIREN MODULATION OF NEUROGENESIS | DCX, NGF, BDNF | LMNA 2587/4885SMN1; SMN2 873/4885ALDH1A1 2863/4885 |
| US-10342817-B2 | Combination therapy using ribavirin as elF4E inhibitor | ELOC, ELP1, ELF3 | LMNA 1229/4885SMN1; SMN2 1869/4885ALDH1A1 2337/4885 |
| US-20190270730-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | NDUFV3, NDUFV1, NDUFV2 | LMNA 1331/4885SMN1; SMN2 795/4885ALDH1A1 226/4885 |
| US-20210145855-A1 | METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS | IMPDH1, IMPDH2, AMPD3 | LMNA 3194/4885SMN1; SMN2 2108/4885ALDH1A1 97/4885 |
| US-20240238323-A1 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES | MTAP, PNP, SARS1 | LMNA 424/4885SMN1; SMN2 761/4885ALDH1A1 1929/4885 |
| US-20210144998-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | PNPO, G6PD, AGXT | LMNA 1773/4885SMN1; SMN2 3745/4885ALDH1A1 2196/4885 |
| US-20230241037-A1 | CROSS-LINKED MEDICATION FOR TREATMENT OF CORONAVIRAL INFECTION AND METHOD OF TREATMENT | ACE2, ACE, TMPRSS4 | LMNA 3540/4885SMN1; SMN2 2655/4885ALDH1A1 1542/4885 |
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | LMNA 4072/4885SMN1; SMN2 1481/4885ALDH1A1 567/4885 |
| US-20220024926-A1 | A1 ADENOSINE RECEPTOR AGONISTS AND METHODS OF USE THEREOF | ADORA1, ADORA2A, ADORA2B | LMNA 1745/4885SMN1; SMN2 1257/4885ALDH1A1 231/4885 |
| US-20170166557-A1 | 6-SUBSTITUTED QUINAZOLINONE INHIBITORS | NDUFV3, NDUFV2, NDUFV1 | LMNA 1496/4885SMN1; SMN2 678/4885ALDH1A1 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.